CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Summary

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).

Timeline

Start

2018-09-07

Primary completion

2020-01-01

Completion

2021-01-01

Drugs

Indications